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Abstract
Background: Understanding trajectories of symptom changes may help gauge treatment response and better
identify therapeutic targets in treatment of acute mania. We examined how symptoms of sleep disturbance, mania,
and psychosis resolved in a naturalistic treatment setting, hypothesizing that improvement in sleep would precede
improvement in manic and psychotic symptoms.
Methods: Charts of 100 patients with admitting diagnoses of bipolar mixed or manic episode were retrospectively
reviewed. Medications and demographic variables were recorded, and the Clinician-Administered Rating Scale for
Mania (CARS-M) mania and psychosis ratings and sleep hours were determined for 8 observation points. Times to
minimum symptom level in each domain were compared via Wilcoxon signed-rank tests. Symptom correlations
and trajectories and medication effects were explored using repeated measures ANOVA and regression models.
Results: Manic and psychotic symptom resolution was linear over the time of hospitalization. In contrast, sleep
showed a slow initial response, followed by rapid increase to peak, preceding peak improvement in mania and
psychosis (p < 0.001). Rate of sleep restoration was a predictor of rate but not of magnitude of treatment response
for symptoms mania and psychosis. Patterns of medication use did not affect symptom trajectories.
Conclusions: In acute mania, improvement in sleep with treatment is dissociable from resolution in symptoms of
mania and psychosis, but there appears to be no therapeutic advantage to patient oversedation. Sleep improves
first and may be both a predictor of the rate of treatment response and a useful therapeutic target.
Keywords: Bipolar disorder, Sleep, Psychosis, Mania
Background
Bipolar disorder is a disorder of mood, which is distin-
guished from other mood disorders by manic episodes –
sustained periods of decreased sleep and increased energy,
as well as elevated or irritable mood and, in some in-
stances, psychosis. The extent to which the symptom do-
mains of sleep disturbance [1, 2], mood, and psychosis are
dissociable processes is unclear. Knowledge of the rela-
tionships between and trajectories of these symptom
domains may help better identify therapeutic targets as a
manic episode progresses from its onset to its resolution.
Studies indicate that sleep disturbance plays a prominent
role in the prodromal phase of bipolar disorder [3, 4].
Animal models indicate that sleep deprivation may trigger
a manic episode [5], while in humans, chronotherapy with
sleep deprivation is effective in elevating mood in de-
pression (via the reset of circadian rhythms disrupted
by CLOCK gene dysfunction) as well as in depression
with psychotic features [6, 7]. Several studies have
suggested that sleep disturbance may be a possible
mechanism for future illness relapse [8, 9], and a recent
review cited sleep deprivation as a main trigger of an
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episode switch [10]. A recent study found that poor
sleep quality continues during euthymia, and that sleep
disturbance may be a prodromal sign or trigger of a
change in mood episode [11]. Finally, studies examining
environmental disturbances to circadian/social rhythms’
contributions to mania onset suggest they do so via sleep
disturbance [12].
In contrast to the relative abundance of studies on the
associations between sleep disturbances and onset of
mania [13–16], we are aware of just one study, a small
retrospective chart review, attempting to assess the
temporal relationship between sleep restoration and reso-
lution of mania [17]. Finally, one double-blind comparison
of the effect of the antipsychotics haloperidol and olanza-
pine on sleep in mania [18] noted differential effects of
these drugs on multiple sleep measures as well as different
trajectories of improvement in sleep and manic symptoms
or psychosis, suggesting a possible influence of sleep-
symptom treatment on the course of mania.
A number of studies examined the relationship between
psychosis and sleep without regard to symptoms of mania.
Individuals at-risk for psychosis compared to healthy con-
trols had poorer sleep quality, more fragmented sleep
rhythms, and circadian rhythms that were not synchro-
nized with dark–light cycles, suggesting a link between
sleep and the onset of psychotic disorders [19, 20]. Early
studies found that sleep variables such as decreased REM
sleep and REM activity differentially affected psychotic
and nonpsychotic depressive patients, and increased sleep
hours and REM activity accompanied improvement in
psychotic symptoms [7, 21]. Finally, a more recent study
on the relationship between psychopathology and sleep in
schizophrenia found that a change in patterns of sleep
preceded any changes in symptom severity [22].
Understanding trajectories of improvement in sleep
and mania during treatment of acute manic episodes
may inform treatment decisions. Specifically, since sleep
disturbance is prodromal to mania onset, partial or even
complete resolution in manic symptoms without sleep
restoration may indicate continuing acute manic episode
warranting further aggressive treatment, despite symp-
tomatic improvement. Similarly, if sleep restoration pre-
cedes and is correlated with improvement in symptoms
of mania, sleep duration may present a useful index of
treatment progress and an easily quantifiable therapeutic
target. Similar considerations would apply to the rela-
tionship of mood and sleep domains with psychosis.
In this context we sought to examine how the symptom
domains of sleep, mania, and psychosis resolve during
naturalistic inpatient treatment and test the following
three hypotheses regarding the trajectories of symptom
resolution: i) as in manic episode onset, sleep disturbance
during episode resolution would be dissociable from
symptoms of mania and psychosis, ii) that sleep would
improve faster than symptoms of the other two do-
mains and the sleep improvement rate would predict
the rates of improvement in mania and psychosis, rather
than the reverse – that symptom changes might precede
improvement in sleep given that hyperarousal or rumin-
ation due to psychosis and mania might affect sleep, and
iii) that the magnitude of sleep disturbance at admission
and magnitude of sleep improvements in the beginning of
the hospitalization would predict the magnitude of
manic and psychotic symptom severity at the end of
hospitalization.
Methods
This retrospective chart review study was approved by
the institutional review board of the Beth Israel Medical
Center of New York (BIMC). Charts were retrieved from
computer storage using Access Anywhere software. All
inpatient psychiatric admissions to BIMC from January
1st, 2003, to January 1st, 2010 were screened for a billing
diagnosis of bipolar disorder, current episode manic or
mixed state. The authors identified 100 completed
clinical charts that fit the inclusion criteria. A chart
was considered completed when it included a patient’s
demographic information, psychiatric history, medica-
tion administration records, symptomatic assessments
by nurses, resident psychiatrists and psychology interns,
and supervising attending psychiatrists, records of any
measures of isolation or restraint due to agitation, and
duration of sleep. Sleep duration was computed from
nurses’ notes based on their morning report of total hours
of sleep for each patient, verified by chart records of their
hourly checks throughout the night.
Sleep and symptom severity data were extracted from
patient charts for each of eight time points: once upon
the patient’s admission, each Monday, Wednesday and
Friday (the days on which MD documentation in charts
was mandatory) for the first two weeks following admis-
sion, and once at discharge, following the schedule on
which psychiatrists write inpatient notes at BIMC.
Demographic information including patient age, sex,
race, substance use/abuse status, and length of stay
were extracted from patient charts (See Table 1). The
medications administered to each patient were also
extracted from patients’ PRISM software medication
administration records throughout the entirety of
hospitalization. Antipsychotics were classified as first
or second generation and were converted to chlorpro-
mazine milligram equivalent doses, while benzodi-
azepine doses were converted to lorazepam milligram
equivalents (See Table 2). Diphenhydramine was the
only antihistamine administered and milligram doses
administered were recorded.
Raters extracted symptomatic severity assessments
from doctors’, nurses’, social workers’, and occupational
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therapists’ chart entries using the Clinician Adminis-
tered Rating Scale for Mania (CARS-M) [23]. The
CARS-M is a 15-item observer-rated scale with two
principle components, mania and psychosis, which have
demonstrated strong inter-rater, test-retest, and internal
reliability, and strong convergence with other rating
scales for mania. The mania domain is measured by the
first 10 items, which assess features like euphoria, irrit-
ability, hypermotor activity, pressured speech, flight of
ideas, distractibility, grandiosity, excessive energy, poor
judgment, and decreased need for sleep. Psychosis is
measured by the final 5 items, which include disordered
thinking, delusions, hallucinations, orientation, and
insight. Each item is scored on a 5-point Likert scale,
ranging from 0 to 5 (absent, slight, mild, moderate, se-
vere, extremely severe), with descriptive clinical an-
chors for each level of severity > 0 [23].
The CARS-M symptom-related information on the
charts was rated by three psychiatrists in their second
through fourth year of residency training, under the
direct supervision of IIG. Each item on the CARS-M at
each time-point was rated by 3 raters, and, when the
three independent ratings did not agree, least difference
criteria were used to achieve a consensus score for each
item as follows: If two clinicians gave the same score on
any given data point, and one clinician gave a different
score, the score given by the two agreeing clinicians was
taken. If all three clinicians disagreed in a contiguous
manner (e.g. 3, 4, and 5), the median score (4 in this
case) was taken. If they disagreed in a noncontiguous
manner (e.g. 2, 4, and 8), the mean of the two closest
scores [3] was taken.
Statistical analysis
To assess and compare trajectories of sleep, CARS-M
mania, and CARS-M psychosis scores, repeated mea-
sures ANOVA was performed assessing each measure
across observation days one through seven (See Table 3).
In a secondary analysis, cumulative doses from observa-
tion days one through seven of benzodiazepine lorazepam
equivalents, first and second generation antipsychotic
chlorpromazine equivalents, and milligrams of diphen-
hydramine were added to the model as covariates to ac-
count for possible differential effects on sleep, mania, and
psychosis. In addition, we considered sex and substance
use as potential confounds.
Because observation day numbers are not a linear
metric of time, we used paired non-parametric Wilcoxon
signed-rank tests to compare time to maximum im-
provement (when the symptoms would reach greatest
sleep hours, and lowest CARS-M subscale scores) over
all observation days excluding observation day one. At
maxima, increases in sleep and decreases in mania and
psychosis measures could either peak or plateau: we use
the term “peak” throughout for simplicity. Observation
day one was excluded to eliminate the possibility of a
patient arriving highly sedated from the ER or from an-
other hospital as a transfer and thus having spuriously
high sleep or low mania or psychosis scores. All statis-
tical analyses were performed with SPSS 16.0.
To test prediction of symptom response by early sleep
duration we examined univariate correlations between
mean sleep on observation days one and two and mean
symptom severity on observation days six and seven. To
test prediction of symptom response by degree of sleep
improvements early in hospitalization we examined
univariate correlations between change in mean sleep
(between mean sleep on observation days one and two
and mean sleep on observation days four and five) and
mean symptom severity on observation days six and
seven. Two observation-day means were used to reduce
noise in the data.
Results
Sample demographics
Patient mean age was 40.5 [13.5] (mean [SD]) years. Length
of stay (LOS) in the hospital ranged from 10 to 189 days,
with a 5 % trimmed mean LOS of 34.4 [24.8] days.
The number of previous psychiatric hospitalizations
reported ranged from 0 to 4, with a mean of 1.4 [1.3]
prior hospitalizations. In the sample of 100, 45 had no
substance use disorder (SUD), 51 had at least one SUD,
and 4 had missing SUD data. Of those with at least 1
SUD, 45/51 had an alcohol use disorder, 31/51 had a
marijuana use disorder, 15/51 had a cocaine use dis-
order, 6/51 had an opiate use disorder, 5/51 were in a
methadone maintenance treatment program, and 4/51
had other substance use disorders. Among 100 patients,
52 were male, and 26 were Caucasian, 15 African
American, 7 Hispanic, 4 Asian, 3 Middle Eastern, 16
other race/ethnicity, and 29 did not have race/ethnicity
recorded.
Sample treatment characteristics
Complete medication administration data were avail-
able for 89/100 charts. The division of each medical
class administered to 89 of the 100 patients during
hospitalization was recorded as follows: 49 patients
received first generation antipsychotics (FGAs), 76
received second generation antipsychotics (SGAs), 70
received mood stabilizers (MSs), and 69 received ben-
zodiazepines (BZD).
In the group of patients who received SGAs, the most
commonly used SGAs were Olanzapine, Risperidone, and
Quetiapine, followed by Aripiprazole and Ziprasidone.
Clozapine and Paliperidone were used least frequently.
Among FGAs, the most commonly used was Haloperidol,
followed by Chlorpromazine, Perphenazine, Fluphenazine,
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and Loxapine. Among mood stabilizers, the most com-
monly used were valproate and lithium. At baseline,
CARS-M mania and psychosis scores were correlated with
each other (r = 0.248, p = 0.013) but not with sleep (mania;
r = −0.144, p = 0.159; psychosis: r = 0.011, p = 0.913).
Table 1 Sociodemographic characteristics and medications of
100 bipolar inpatients admitted with manic or mixed episode
Variables n % Mean ± SD






African American 15 15.0
Hispanic 7 7.0
Asian 4 4.0
Middle Eastern 3 3.0
Other 16 16.0
Not recorded 29 29.0




At least one substance use disorderb 51 51.0
Alcohol use disorder 45 88.2
Marijuana use disorder 31 60.8
Cocaine use disorder 15 29.4
Opiate use disorder 6 11.8
Methadone maintenance 5 9.8
Other substance use disorder 4 7.8
Number of patients with
complete medication records
89 89.0
Number of medications per patientc 4.11 ± 1.77
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Antihistamines (Diphenhydramine) 39 43.8
Number of patients on any antipsychotic 88 98.9
Number of patients on mood
stabilizer and antipsychotic
68 76.4
a5 % trimmed mean
bPercentages within category
cMean calculated for patients with complete medication records (n = 89)
Table 2 Equivalent doses for antipsychotics and benzodiazepines
Drug Milligrams of Chlorpromazine Equivalent














Drug Milligrams of Lorazepam Equivalent
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Sleep, mania, and psychotic symptom trajectories
As expected, repeated measures ANOVA revealed
significant improvements over time in sleep hours,
mania, and psychosis scores (p < 0.001) for all mea-
sures (See Table 3a). Examination of the trajectories of
sleep, mania, and psychosis indicated significant linear
components for all measures with p < 0.001 (See Table 3b,
Fig. 1).
In addition, we found a significant cubic term for
change in sleep (F = 4.04, p = 0.05), accounting for the
generally sigmoidal trajectory (See Fig. 2) of initial slow
improvement followed by rapid increase in sleep hours
which then leveled off. For mania, we found a significant
quadratic term (F = 4.61, p = 0.03), accounting for the
lower rate of improvement in observations four through
seven versus observations one through three. Maximal
improvement in mean sleep was reached in observation
day five, whereas maximal improvements in mean mania
and psychosis scores were observed in observation day
seven.
When the model was covaried for cumulative doses of
sedating medications (benzodiazepines, first and second
generation antipsychotics, and antihistamines) significant
between subject differences were found only for cumulative
benzodiazepine dose (F = 4.36, p = 0.01), however there
were no significant interactions between cumulative doses
and time in the over-all multivariate within-subjects model.
Thus, in multivariate analysis, there were no significant
changes in symptom trajectory associated with medication
use (See Table 3c-da-b). Further, when the model was co-
varied for age, no significant effects were found.
In univariate analyses however, there were significant
within subjects effects of cumulative benzodiazepine
dose on mania trajectories (cumulative dose*observation
day F = 2.119, p = 0.05). In other words, over the course of
their hospitalizations, patients receiving higher cumulative
Table 3 Results of repeated measures ANOVA
a. Within subjects univariate tests
Measure Type III Sum of Squares df Mean Square F Sig.
Sleep 84.88 6 14.15 5.55 <.001
Mania 4042.82 6 673.80 54.14 <.001
Psychosis 1117.91 6 186.32 44.68 <.001
b. Within subjects contrasts
Measure Type III Sum of Squares df Mean Square F Sig.
Sleep Linear 70.58 1 70.578 17.83 <.001
Sleep Quadratic 4.43 1 4.429 1.55 .22
Sleep Cubic 8.81 1 8.813 4.04 .05
Mania Linear 3960.19 1 3960.187 134.66 <.001
Mania Quadratic 58.65 1 58.647 4.61 .03
Mania Cubic 19.73 1 19.734 2.01 .16
Psychosis Linear 1117.49 1 1117.487 108.57 <.001
Psychosis Quadratic .06 1 .056 .01 .92
Psychosis Cubic .03 1 .028 .01 .92
c. Multivariate tests of between subjects effects
Measure Pillai’s Trace df Mean Square F Sig.
BZD cumulative dose .14 78 3.00 4.36 .01
DPH cumulative dose .06 78 3.00 1.61 .19
FGA cumulative dose .05 78 3.00 1.33 .27
SGA cumulative dose .05 78 3.00 1.21 .31
d. Multivariate tests of within subjects effects
Measure Pillai’s Trace df Mean Square F Sig.
Time .56 63 18.00 4.40 <.001
BZD dose * Time .32 63 18.00 1.62 .08
DPH dose * Time .26 63 18.00 1.24 .26
FGA dose * Time .19 63 18.00 .82 .67
SGA dose * Time .21 63 18.00 .94 .54
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benzodiazepine doses had more pronounced nonlinear
distortions to their manic symptom trajectories, with
tendencies toward higher initial levels of mania which im-
proved more rapidly at first before plateauing.
In relation to sleep and psychosis, no medication showed
significant between subjects effects. In relation to mania,
only cumulative benzodiazepine doses showed significant
between subjects effects (F = 12.899, p = 0.001), while cu-
mulative antihistamine doses were marginally significant
(F = 3.197, p = 0.078), both being higher in patients with
higher mania scores. Further, when the presence or
absence of any substance use or of any stimulant use were
included in the model as between subjects factors, no sig-
nificant effects were found either between or within sub-
jects on any symptom measure.
Sex effects on symptom trajectories
In a secondary analysis we found that sex had a marginally
significant overall impact on sleep trajectory (F = 2.076,
p = 0.054), with a significant linear effect in the within-
subjects contrasts analysis (F = 7.579, p = 0.007), but


























Fig. 1 Trajectory of mania, psychosis, and sleep across 7 observations (admission through 2 weeks). Percentage of maximum sleep (hours) and






























Fig. 2 Trajectory of sleep across 7 observations (admission through 2 weeks). Estimated marginal means of sleep (hours) versus observation number
Galynker et al. BMC Psychiatry  (2016) 16:98 Page 6 of 9
while there were no sex differences in mania and psychosis
trajectories, on admission, sleep disturbance in men was
less severe but improved more slowly than sleep disturb-
ance in women (See Fig. 2).
Relative times to peak improvement for sleep, mania,
and psychosis
As hypothesized, paired Wilcoxon signed-rank tests re-
vealed that the observation day during which patients
achieved the maximum hours of sleep (mean observa-
tion day 4.69) significantly preceded the observation day
during which they received the minima scores on the
illness severity scales (mania trough mean observation
day 6.98, p < 0.0005; psychosis trough mean observation
day 7.3, p < 0.0005; CARS-M total score trough mean
observation day 7.74, p < 0.0005). Shorter times to peak
improvement in mania versus psychosis did not reach
significance (paired Wilcoxon signed-rank test two-tailed
p = 0.123).
There were no significant differences between men
and women in time to peak improvement in any symp-
tom domain, though time to peak improvement in
mania scores was marginally lower for women than men
(Mann–Whitney U two-tailed p = 0.1).
Relation between sleep and manic and psychotic
symptom responses
As expected, level of mania on observation day one
was significantly correlated with level of mania aver-
aged across observation days six and seven (r = 0.404,
p < 0.0005) and severity of psychosis on observation
day one was significantly correlated with severity of
psychosis averaged across observation days six and
seven (r = 0.407, p < 0.0005).
As hypothesized, time to peak sleep correlated signifi-
cantly with time to lowest mania rating (Spearman’s
rank r = 0.302, two-tailed p = 0.002) and with time to
lowest psychosis rating (Spearman’s rank r = 0.265, two-
tailed p = 0.008). In other words, rate of sleep restor-
ation was a moderate predictor of rate of treatment
response for symptoms of mania and psychosis.
There were no significant correlations between time to
peak sleep and manic (rho = 0.13, p > 0.1) or psychotic
symptom severity (rho = 0.16, p > 0.1) averaged across
observation days six and seven (i.e., after approximately
two weeks of hospitalization). Likewise, early sleep gains
were uncorrelated with manic (rho = 0.11, p > 0.1) or
psychotic (rho = −0.07, p > 0.1) symptom severity aver-
aged across observation days six and seven. In other
words early restoration of sleep was not a predictor of
the magnitude of treatment response for symptoms of
mania and psychosis.
Discussion
This study examined the trajectories of and relationships
between sleep, manic symptoms, and psychotic symp-
toms in bipolar patients hospitalized for a manic episode
with the hope of identifying preferred therapeutic targets
at different times in the course of treatment of mania.
To our knowledge this is the first study to do so.
Our first hypothesis, that sleep disturbance would be
dissociable from symptoms of mania and psychosis, was
supported. Sleep resolution followed a sigmoid curve
with initial slow improvement followed by a rapid change
while mania and psychosis improvements were linear.
The results further indicated that sleep disturbance
would resolve more rapidly than manic and psychotic
symptoms, and that improvement in sleep would predict
improvement in other domains, such that time to peak
sleep would correlate with time to peak improvement in
mania and psychosis. Thus our second hypothesis was
also supported – maximal sleep improvements robustly
preceded those in other domains and rate of sleep im-
provement was in this way a predictor of rate of improve-
ment in manic and psychotic symptoms. The alternative
to our second hypothesis, that symptom changes might
precede improvement in sleep due to sleep disturbances
caused by psychosis and mania was also partially sup-
ported, as some decline in manic and psychotic symptoms
was observable prior to significant improvement in sleep
duration. In short, our findings suggest that in treatment
of mania, sleep should be assessed separately from both
mania and psychosis and that sleep may be a useful prog-
nostic guide in the treatment of manic episodes.
Our third hypothesis, that hours of sleep near time of
admission and sleep improvement rates would predict the
magnitude of improvement in manic and psychotic symp-
toms achieved over the first 2 weeks of hospitalization,
was not supported. This finding suggests that more sleep
does not mean less mania and psychosis. In other words,
over-sedating patients does not result in fewer symptoms
of mania and psychosis.
Our findings suggest that in treatment of mania, sleep
needs to be monitored separately from mania and psych-
osis. Not unexpectedly, early severity in each domain was
found to be the strongest predictor of the subsequent
course in that domain. Still, although improvement in
sleep and mania/psychosis are relatively independent pro-
cesses, our data suggests that symptoms of mania and
psychosis typically improve only after improvement in
sleep, suggesting that early in treatment of acute mania,
sleep may be both a good indicator of treatment progress
and a good or even preferred treatment target.
Our finding that the sleep improvement curve is sig-
moid, with initial relative persistence of sleep disturb-
ance for about a week followed by rapid improvement
and normalization by the middle of the second week,
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has important clinical implications. Due to the slow ini-
tial rate of sleep restoration, particularly in males, in
many cases partial or even complete resolution in manic
symptoms in the first week of treatment may precede
sleep restoration, creating a misleading impression that
the index manic episode has been successfully treated
allowing hospital discharge.
Our results suggesting a sex difference in sleep dis-
turbance and rates of sleep restoration are supported by
a previous study on gender-specific sleep in bipolar
disorder, which found that bipolar women reported
poorer sleep quality, and poor sleep quality at episode
onset predicted more severe and variable manic episodes
[24]. On the other hand, our finding that sleep in men
improved more slowly is new, and, if replicated suggests
that sleep as a treatment target can be addressed and
managed differently by gender.
However, regardless of gender, only normalization of
both domains will reliably signify the end of the acute
manic episode and warrant a switch to maintenance
treatment of bipolar disorder. Thus, discharging patients
having continuing sleep disturbance even with marked
improvement in mania and psychosis means incomplete
resolution of the acute manic episode which may result
in a need for hospital readmission for further aggressive
treatment.
Finally, our results finding a lack of correlation between
the magnitude of sleep disturbance (or improvement) and
the severity of symptoms of mania and psychosis indicate
that excessive sleep may not be related to complete reso-
lution of mania and psychosis. In other words, it appears
that excessive sleep in treatment of mania may not neces-
sarily be therapeutic.
These results should be considered in the light of
several limitations, including the retrospective chart
review design, and the use of clinical rather than stan-
dardized diagnoses. Further, CARS ratings were based
on clinical documentation rather than direct patient ob-
servation. However, previous studies have demonstrated
the feasibility of making clinical ratings based on psychi-
atric medical records [25, 26], and the combination of
multiple observer data and multiple rater scoring with
concrete descriptive anchor points for symptom severity
ranking provided by the CARS provides a strong basis
for extracting meaningful scores from the medical rec-
ord. Another important potential limitation is the reli-
ance on nursing rather than physiological assessment of
sleep duration, though this has been shown to be a rea-
sonably accurate measure in psychiatric inpatients [27].
In addition, this paper focused on sleep duration as mea-
sured by the number of hours, and did not measure
sleep quality either subjectively or in terms of sleep effi-
ciency, i.e., the ratio of time spent asleep to the time
spent in bed. Finally, there was no assessment of
depressive symptoms and thus the prevalence and possible
effects of mixed episodes, as well as the course of reso-
lution of mixed depressive symptoms, were not accounted
for.
Conclusions
In sum, inpatient treatment of acute manic episodes is
effective, with dissociable trajectories for improvement
in sleep vs. improvement in mania and psychosis. Thus,
both early normalization of sleep with continuing symp-
toms of mania and psychosis, and normalization of
manic and psychotic symptoms with continuing sleep
disturbance warrant continuation of treatment of the
index manic episode.
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